Journal
FRONTIERS IN MEDICINE
Volume 8, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fmed.2021.636188
Keywords
dendritic cells; HMGB1; signal transduction pathway; systemic lupus erythematosus; mTOR inhibitor
Categories
Funding
- National Natural Science Foundation of China [81770041, 81860298]
Ask authors/readers for more resources
The study found that HMGB1 can activate myeloid dendritic cells by upregulating the mTOR pathway in peripheral blood of SLE patients, leading to increased production of pro-inflammatory cytokines. Rapamycin was able to inhibit HMGB1-induced activation of dendritic cells and secretion of pro-inflammatory cytokines.
Research has shown that HMGB1 can activate dendritic cells (DCs), but its molecular mechanisms are not clear. In this study, we reported that the myeloid dendritic cells (mDCs) were activated in the peripheral blood of SLE patients, and the activation of mDCs was associated with the up-regulation of HMGB1 and mTOR. After stimulated by HMGB1, expression of mTOR and its substrates P70S6K and 4EBP1 in dendritic cells increased considerably (P < 0.01). The expression of HLA-DR, CD40, and CD86 on dendritic cells also significantly increased following these stimuli (P < 0.01). In addition, stimulation with HMGB1 enhanced cytokine (IL-1 beta, IL-6, and TNF-a) production in dendritic cells. In contrast, the HMGB1-mediated expression of HLA-DR, CD40, and CD86 on dendritic cells and production of IL-1 beta, IL-6, and TNF-alpha were reduced by rapamycin. Rapamycin can inhibit HMGB1-induced activation of mDCs and secretion of pro-inflammatory cytokines. These findings indicated that HMGB1activates mDCs by up-regulating the mTOR pathway in SLE.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available